Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent BioSolutions has entered into $186.6m contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen (rPA) anthrax vaccine.
Subscribe to our email newsletter
Emergent BioSolutions’ rPA anthrax vaccine candidate is a purified recombinant protective antigen protein formulated with an alum adjuvant and is designed to induce antibodies that neutralise anthrax toxins.
As per the terms of the agreement, the base value is expected to fund activities related to process characterisation and assay validation, as well as formulation and stability studies.
Milestone-based options include completion of a Phase II clinical study and non-clinical efficacy studies, process validation, as well as consistency lot manufacture.
Emergent BioSolutions chairman and CEO Fuad El-Hibri said that the award solidifies Emergent’s anthrax franchise.